1. Home
  2. KNDI vs IFRX Comparison

KNDI vs IFRX Comparison

Compare KNDI & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

KNDI

Kandi Technologies Group Inc

HOLD

Current Price

$1.07

Market Cap

67.8M

ML Signal

HOLD

Logo InflaRx N.V.

IFRX

InflaRx N.V.

HOLD

Current Price

$1.04

Market Cap

67.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KNDI
IFRX
Founded
2002
2007
Country
China
Germany
Employees
N/A
N/A
Industry
Auto Manufacturing
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
67.8M
67.0M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
KNDI
IFRX
Price
$1.07
$1.04
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$8.50
AVG Volume (30 Days)
183.5K
635.9K
Earning Date
03-13-2026
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$104,035,613.00
$73,729.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$1,054.36
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.78
$0.71
52 Week High
$1.81
$2.77

Technical Indicators

Market Signals
Indicator
KNDI
IFRX
Relative Strength Index (RSI) 62.64 46.52
Support Level $0.92 $0.93
Resistance Level $1.05 $1.10
Average True Range (ATR) 0.07 0.08
MACD 0.02 -0.00
Stochastic Oscillator 90.24 34.21

Price Performance

Historical Comparison
KNDI
IFRX

About KNDI Kandi Technologies Group Inc

Kandi Technologies Group Inc is engaged in developing, manufacturing, and commercializing fully electric vehicle products and related technologies. Its products mainly consist of EV parts, EV products, and off-road vehicles, including All-Terrain Vehicles (ATVs), UTVs, go-karts, electric scooters, electric self-balancing scooters, and associated parts, and Lithium-ion cells, etc. The company generates maximum revenue from the sale of Off-road vehicles and associated parts. Geographically, it derives maximum revenue from the United States and other countries, followed by China.

About IFRX InflaRx N.V.

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

Share on Social Networks: